Our Story

CuraVac was founded in 2002 by Dr. Stéphane Huberty, a Belgian medical doctor who suffered from Myasthenia Gravis. Soon after, the company acquired the complementary peptide patent, raised funds and got organized as a management company at the center of a network of collaborations and sub-contracting companies. The original discoverer of the vaccine production technique, Professor J. Edwin Blalock also joined CuraVac as a consultant. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Lorem ipsum dolor sit amet. pulvinar dapibus leo.Lorem.pulvinar.pulvinar dapibus leo.Lorem ipsum dolor sit amet.

Desperate for a Treatment, One Physician Heals Himself
Frustrated by Lack of Interest From Drug Companies, a Belgian Doctor
Pursues Own Research to Help Cure His Disease
By John W. Miller

Myasthenia Gravis

Myasthenia Gravis (MG) is a rare, but not exceptional, autoimmune disease that is diagnosed (Prevalence) in one in seven thousand (1.33/10,000) to one in five thousand (2/10,000) of the population. On top of these existing cases, each year there are 15 new cases per 1,000,000 of the population (Incidence). In total, over a 5 year period, in Europe, U.S.A. and Japan alone, more than 250,000 diagnosed MG patients need treatments.

MG is characterized by muscular fatigue leading to extreme weakness. The fatigue is caused by the loss of ability to convert nerve impulses into muscle contraction. Underlying these symptoms is an autoimmune disease. The patient’s immune system produces antibodies that attack the docking sites, or receptors, on the nerve/muscle interface.

Current treatment options for MG consist of symptomatic and causal treatments.

At present, there is no cure on the market.

The struggles of living with MG

Managing the disease is possible, but it often means enduring ongoing weakness and grappling with challenging side effects. The founder and patient, Dr. Stéphane Huberty, tells us more about the struggles he experienced when he was ill.

The MG Therapeutic Vaccine

CuraVac is bringing a revolutionary treatment, the First MG therapeutic vaccine, that aims at greatly improving or even curing Myasthenia Gravis with only a few Vaccine injections.

CuraVac is presently preparing a phase 2 efficacy clinical trial with a more potent formulation of the MG Therapeutic Vaccine : CV-MG02.

June, 2014
CuraVac gears up to the next level: 1st MG patients injected in March 2015 Creation of an Independent Advisory Board.

December, 2015
MYASTERIX Phase 1b clinical study is launched to test a therapeutic vaccine for Myasthenia Gravis.
Read the press release

February, 2016
Myasthenia gravis: CuraVac launches phase 1b study in patients.
Read the press release

June, 2018
The First-in-Human Phase 1b Safety Clinical Trial of CuraVac’s Potential Myasthenia Gravis Therapeutic Vaccine Succesfully Meets its Safety Primary End Points.
Read the press release

Links that might help

List of associations

Support group


Online Survey

Contact us

This site is registered on wpml.org as a development site.